Download or read book Characterization of Genetic Alterations in Ovarian Cancer Associated with Chemotherapy Response written by Lovisa Österberg and published by . This book was released on 2009 with total page 43 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Characterization of Genetic Alterations in Ovarian Cancer written by and published by . This book was released on 2000 with total page 0 pages. Available in PDF, EPUB and Kindle. Book excerpt: Ovarian cancer is a highly lethal malignancy specific to women. We have set up the infrastructure at Mayo for an Ovarian Cancer Research Program utilizing the rich resources of clinical material. This Program Project focuses specifically upon a genetic analysis of ovarian cancer using the transcriptional profiling strategies of cDNA microarrays and subtraction suppression hybridization. We have linked the work of cancer geneticists with cell biologists to begin to understand the functional role that some of the consistently aberrantly-regulated genes play in ovarian cancer development. There are three projects in this grant. The first project focuses on the identification of consistently down-regulated genes in ovarian cancer. The second project focuses on the role of gene amplification in familial versus sporadic ovarian cancer. The third project is to characterize genes that are consistently down-regulated in ovarian tumors that are derived from within common fragile site regions. This Program Project is centered within a larger institutional effort to better understand the biology of the development of ovarian cancer and to devise better strategies for the prevention, early detection, and treatment of this lethal disease.
Download or read book Genomic Alterations in Residual High grade Serous Ovarian Cancer After Neoadjuvant Chemotherapy and Their Impact on Survival written by David Octeau and published by . This book was released on 2018 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: "Background: The prognosis of patients afflicted with high-grade serous ovarian cancer remains poor and a deeper molecular understanding of the disease is required to improve treatment strategies. Tumor biomarkers, such as mutations in BRCA1 and BRCA2, and aberrant expression profiles, have been linked to improved response in patients with high-grade serous ovarian cancers (HGSC) undergoing primary debulking surgery (PDS). Recently, the use of chemotherapy prior to surgery, neoadjuvant chemotherapy (NACT), has become more widely used. While large-scale genomic studies have detailed the molecular landscape of tumors from patients that underwent primary debulking surgery (PDS) and correlated the identified subgroups to survival, none have done the same for the group of patients with residual tumor after NACT. Residual HGSC after NACT may represent a subset of disease enriched for molecular features of resistance.Objective: Describe the underlying genomics of NACT-treated HGSC and correlate them to patient progression- free survival (PFS) and overall survival (OS).Methods: Tumor samples were collected from patients with stage III or IV HGSC before and following neoadjuvant chemotherapy (NACT cohort, n = 57 and PDS cohort, n = 30). Tumor content was validated by histologic examination. Gene expression analysis was performed using a tailored NanoString-based assay, while next generation sequencing was performed on the MiSeq platform. Semi-supervised clustering, gene set analyses, and the appropriate survival models were used to assess the associations between genetic alterations and survival.Results: Semi-supervised, internally validated consensus clustering of gene expression data revealed two patient clusters with prognostic relevance. The association with overall survival remained significant after controlling for clinical variables (OS: p=0.0003). Pathway based analysis of the differentially expressed genes between the Good and the Bad outcome groups revealed high cell cycle and DNA repair gene expression, and actionable targets in the Bad outcome group. Mutational analysis revealed relatively low TP53 mutation frequency in both NACT-treated group, but TP53 mutation status was not associated with survival.Conclusions: A partial genomic profiling of the intratumoral molecular characteristics observed after NACT in high grade serous ovarian cancers revealed molecular subtypes with prognostic significance." --
Download or read book Diagnosis and Management of Ovarian Disorders written by Albert Altchek and published by Elsevier. This book was released on 2003-09-04 with total page 595 pages. Available in PDF, EPUB and Kindle. Book excerpt: This updated second edition of Diagnosis and Management of Ovarian Disorders provides thorough, yet succinct insight into the ever-changing realm of ovarian disorders. It presents a novel multidisciplinary approach to the subject as described by clinicians, surgeons, pathologists, basic scientists and related medical researchers. Topics covered include reproductive technology, early diagnosis of ovarian cancer, and management of menopause among others. The breadth of information provided by this book will appeal to clinicians and researchers involved in the study and treatment of ovarian disorders. KEY FEATURES* Includes updated information on early diagnosis of ovarian cancer* Reviews new diagnostic techniques for ovarian disorders* Discusses latest information on reproductive technology* Presents translational treatment linking laboratory research with clinical medicine
Download or read book Ovarian Cancers written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2016-04-25 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.
Download or read book Epi genetic Characterization of Chemotherapy Response in Ovarian Cancer written by Tushar Tomar and published by . This book was released on 2016 with total page 198 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Ovarian Cancers written by National Academies of Sciences, Engineering, and Medicine and published by National Academies Press. This book was released on 2016-05-25 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.
Download or read book Holland Frei Cancer Medicine written by Robert C. Bast, Jr. and published by John Wiley & Sons. This book was released on 2017-03-10 with total page 2004 pages. Available in PDF, EPUB and Kindle. Book excerpt: Holland-Frei Cancer Medicine, Ninth Edition, offers a balanced view of the most current knowledge of cancer science and clinical oncology practice. This all-new edition is the consummate reference source for medical oncologists, radiation oncologists, internists, surgical oncologists, and others who treat cancer patients. A translational perspective throughout, integrating cancer biology with cancer management providing an in depth understanding of the disease An emphasis on multidisciplinary, research-driven patient care to improve outcomes and optimal use of all appropriate therapies Cutting-edge coverage of personalized cancer care, including molecular diagnostics and therapeutics Concise, readable, clinically relevant text with algorithms, guidelines and insight into the use of both conventional and novel drugs Includes free access to the Wiley Digital Edition providing search across the book, the full reference list with web links, illustrations and photographs, and post-publication updates
Download or read book Identification and Characterization of Candidate Tumor Suppressor Genes Potentially Involved in the Etiology of Ovarian Cancer written by David Charles Schultz and published by . This book was released on 1997 with total page 696 pages. Available in PDF, EPUB and Kindle. Book excerpt: Over the last century it has become widely accepted that cancer is a genetic disease. Initiation and progression of cancer results from the accumulation of mutations in at least three classes of cellular genes. In this aspect the genetics of ovarian cancer have remained poorly understood with respect to other diseases. During tumorigenesis, many of the documented changes in cellular DNA involve inactivation of tumor suppressor genes. In this aspect, molecular analyses of ovarian cancer specimens indicate that several tumor suppressor genes may be involved in the etiology of this disease. Loss of heterozygosity for polymorphic markers on a chromosome arm is often indicative of the inactivation of a tumor suppressor on that chromosome based on Knudson's "two-hit" hypothesis. Allelic loss studies in a large series of ovarian tumors identified several candidate tumor suppressor loci on chromosome 9. Mutational analysis of CDKN2A/p16 on 9p21 in ovarian tumors revealed a minor role for the inactivation of this gene in ovarian cancer. Overall, these studies suggest the potential involvement of a gene or genes on chromosome 9q in the progression of this disease.
Download or read book Characterization of Novel Epigenetic Targets in Ovarian Cancer written by Zhi Qiang Wang and published by . This book was released on 2014 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Identification of Genetic Changes in Ovarian Serous Epithelial Carcinoma Associated with Resistance to Chemotherapy microform written by Marcus Bernardini and published by National Library of Canada = Bibliothèque nationale du Canada. This book was released on 2004 with total page 190 pages. Available in PDF, EPUB and Kindle. Book excerpt: The objective of this project was to use high resolution microarray comparative genomic hybridization (CGH) to identify differentiating regions of genomic imbalance between epithelial ovarian tumors resistant and sensitive to chemotherapy. Our analysis has confirmed the presence of copy number alterations At specific chromosomal loci in these tumors. Gains at 1q, 3q, 8q, 12p and 20q as well as losses at 1p, 4q, 6q, 8p, 9q, 13q, 16q 17p, 18q, are consistent with reported changes in the literature. The improved resolution of array CGH has further allowed us to determine important discriminating regions in these two tumor sets. These regions include 1q42.3, 6q25.3, 13q12.3 and 17q25.3. Two of these regions have been identified in previous work and another contains a gene identified as playing a role in chemotherapy response. Once refined, these regions may be used as markers to identify resistance to chemotherapy prior to initiation of treatment.
Download or read book Surgery for Ovarian Cancer written by Robert E. Bristow and published by CRC Press. This book was released on 2019-02-21 with total page 437 pages. Available in PDF, EPUB and Kindle. Book excerpt: Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.
Download or read book Ovarian Cancer Biomarkers written by Khalid El Bairi and published by Springer Nature. This book was released on 2021-10-09 with total page 236 pages. Available in PDF, EPUB and Kindle. Book excerpt: This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.
Download or read book Precision Medicine Oncology written by Lorna Rodriguez-Rodriguez and published by Rutgers University Press. This book was released on 2019-09-13 with total page 123 pages. Available in PDF, EPUB and Kindle. Book excerpt: Precision medicine is rapidly becoming the standard-of-care for the treatment of cancer patients. This is made possible, in part, by the ready availability and reasonable costs of comprehensive DNA and RNA sequencing assays. However, precision medicine is complex and incorporates entirely new types of data and treatment paradigms that are outside of the training of most oncologists in practice today. Precision Medicine Oncology: A Primer is a concise review of the fundamental principles and applications of precision medicine, intended for clinicians, particularly those working in oncology. It provides an accessible introduction to the technological advances in DNA and RNA sequencing, gives a detailed overview of approaches to the interpretation of molecular test results and their point-of-care implementation for individual patients, and describes innovative clinical trial designs in oncology as well as characteristics of the computational infrastructures through which massive quantities of data are collected, stored, and used in precision medicine oncology.
Download or read book Recueil factice d articles de presse concernant Jane Arnoux written by and published by . This book was released on 2005 with total page 271 pages. Available in PDF, EPUB and Kindle. Book excerpt:
Download or read book Positive Results written by Joi L. Morris and published by Prometheus Books. This book was released on 2010-06-03 with total page 397 pages. Available in PDF, EPUB and Kindle. Book excerpt: This unique and important guidebook is a single, comprehensive source of information and advice to help women (and some men) at high risk for breast and for ovarian cancer because of family history and genetic profile. One part memoir, three parts "how to" manual, Positive Results explains in a clear and steady manner the myths and realities of "the breast cancer genes." It lays out all the options in easy-to-follow, compassionate language. It will help women and men decide if they want to pursue genetic testing, guide them in interpreting their test results, and give them a sound basis for making the life-saving decisions required to manage their risks. Authors Joi Morris and Dr. Ora Karp Gordon cover all of the latest medical options, including genetic testing for breast cancer risk, breast cancer surveillance, assessing risk, mastectomy and breast reconstruction techniques, ovarian cancer surveillance, surgery, managing menopause, and cancer risks in men who carry mutations on BRCA genes. Along the way, Joi tells her personal story and that of other women and men who have made the gut-wrenching decisions required to survive in this world of astronomical risk. At the age of forty-two, Joi learned that she has a genetic mutation on a gene known as BRCA2. The test results meant that her risk of getting breast cancer could be as high as 84 percent by age seventy, and that her risk for ovarian cancer was also high. Compounding her risk was the fact that her mother had developed breast cancer in her forties. After much research and consultation, the result of which is this book, Joi made the difficult decision of undergoing prophylactic mastectomies. This straightforward and practical approach combined with the poignant personal experience of a woman at risk facing these challenging decisions will provide readers with the feeling that they have had the benefit of a long conversation with both a trusted physician and a friend who has just gone through the same uncertainties they are facing.
Download or read book Precision Medicine Tumor Boards Applicability of Personalized Treatment Concepts in Ovarian Cancer written by Stefanie Aust and published by . This book was released on 2017 with total page pages. Available in PDF, EPUB and Kindle. Book excerpt: Background: Treating late-stage cancer according to its genetic mutations is the goal of precision medicine tumor boards (PMTB) that gain importance along with the advances and cost reduction in next generation sequencing (NGS) techniques. Still, their clinical applicability differs according to tumor origin and has been evaluated in detail for Ovarian Cancer patients within this analysis. Methodology: All ovarian cancer patients whose molecular profile was discussed in a PMTB at the Medical University of Vienna, Austria, from 2015 to 2018 were included in this retrospective analysis (n=33). Not only the NGS results, immunohistochemical (IHC) profiles and respective recommended targeted treatments were determined, but especially the patient characteristics related to actual treatment implementation, duration and outcome. Results: In 82% at least one mutation, deletion or amplification could be detected. The most frequently altered genes were p53 and PIK3CA, followed by BRCA1, BRCA2, and KRAS. A total of 73% had potentially actionable gene alterations and/or a respective IHC expression profile resulting in a treatment recommendation. Thereof, 7 patients (29%; with 2 to 4 previous lines of standard treatment) received the respective therapy. In 71% the allocated treatment was not administered due to: poor performance status (patients were referred to palliative/hospice care, n=9; or died immediately after the PMTB, n=2); patients received an alternative therapy (n=4); patients were further treated in another clinic (n=2); Conclusion: Even though a personalized treatment recommendation can be derived frequently, the current treatment implementation in clinical practice remains limited especially due to the poor general condition of ovarian cancer patients after exploitation of standard treatment. However, as each tumor is unique, the obtained molecular genetic data and related clinical characteristics are valuable and will feed the future development of pathway-based drug discovery.
